There is a lot of anger and frustration among the shareholders. However if you see the history of this company and the possible future, the company is going through a transition phase. The pharma industry is very tough and they do not allow new companies to come and grow. Novavax has got the opportunity (through Covid) to make a transition from an experimental company (no revenue) to a product company (expected $B revenue). This is remarkable for a company who struggled for the last 35+ years and did not launch a product. Now is the perfect time to buy back (by the company) at least 10% of the share (costs ~670M) and lead the way for investors to get into ~$20B-$25B company. Many of the big investors will come forward as they start to see the revenue and the profit this year 2022. For a pr